Entropin Inc., of Indio, Calif., appointed Bruce Manning to its board.

Epicyte Pharmaceutical Inc., of San Diego, added Neil Cowen as vice president of strategic development.

EpiGenesis Pharmaceuticals Inc., of Cranbury, N.J., appointed Anthony Sandrasagra vice president, discovery; added Mathew Pazaryna as chief financial officer; and said Viviana Amzel joined the company as general counsel, chief intellectual property officer and corporate secretary.

Genaissance Pharmaceuticals Inc., of New Haven, Conn., promoted Melodie Henderson to vice president, intellectual capital and licensing.

Genset SA, of Paris, appointed Robert Abarbanel chief information officer and chief technical officer.

Hyseq Inc., of Sunnyvale, Calif., added William Bennett as senior vice president research.

Insmed Inc., of Richmond, Va., appointed Melvin Sharoky to its board.

Matritech Inc., of Newton, Mass., added Eva Singletary to its breast cancer medical advisory board.

MDS Proteomics, of Toronto, a majority-owned subsidiary of MDS Inc., added Scott Rocklage to its board.

National Center for Genome Resources, of Santa Fe, N.M., appointed Miguel Rios interim president and CEO.

National Institutes of Health, of Bethesda, Md., named Edmund Tramont director of the division of AIDS, part of the National Institute of Allergy and Infectious Diseases.

Origenix Technologies Inc., of Laval, Quebec, appointed Robert Deziel director of chemistry.

Oxigene Inc., of Watertown, Mass., appointed Tammy Bishop director of investor relations and corporate communications.

Paladin Labs Inc., of Montreal, appointed Samira Sakhia chief financial officer.

Pharmacyclics Inc., of Sunnyvale, Calif., elected Loretta Itri to its board.

PPD Inc., of Wilmington, N.C., appointed Judd Hartman as general counsel.

Praecis Pharmaceuticals Inc., of Waltham, Mass., elected Patrick Zenner to its board.

Protarga Inc., of King of Prussia, Pa., named Christopher Black vice president, preclinical development and EveMarie Damiano vice president, regulatory affairs and quality.

Regeneron Pharmaceuticals Inc., of Tarrytown, N.Y., appointed Charles Poole vice president, investor relations.

Renovo Ltd., of Manchester, UK, appointed Robin Cridland business development director, effective Sept. 1.

Salus Therapeutics Inc., of Salt Lake City, appointed Cy Stein to its board.

SangStat Medical Corp., of Fremont, Calif., named Nicholas Simon to its board.

Seattle Genetics Inc., of Bothell, Wash., appointed Morris Rosenberg vice president, development.

Sonus Pharmaceuticals Inc., of Bothell, Wash., appointed Nagesh Palepu senior vice president and chief scientific and technology officer.

Targeted Genetics Corp., of Seattle, said its majority-owned subsidiary, CellExSys Inc., appointed Phillip Maples vice president, technical operations.

No Comments